ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Senores Pharmaceuticals (SENORES.NSE)
Senores Pharmaceuticals share price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - General · National Stock Exchange of India · India
₹1,246▲ +2.48%
Prices as of Oct 26, 2026 · INR
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Senores Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Senores Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Senores Pharmaceuticals a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₹1,159 and ₹1,335; in 9 out of 10, between ₹1,023 and ₹1,513. Estimated annual volatility is 39%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₹57.7B
- Market cap (USD)
- $610M
- P/E ratio
- 44.2
- 52-week high
- ₹1,599
- 52-week low
- ₹706.00
- Revenue (12 months)
- ₹6.8B
- Operating margin
- 24.3%
- Net margin
- 18.7%
What this means
ATLAS does not publish a fair value for SENORES.NSE right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks SENORES.NSE has traded between ₹706.00 and ₹1,599. Today it is 22.1% below that high and 76% above its low.
On the business: net margin is 18.7%; it trades at 44.2 times earnings.
About the company
Senores Pharmaceuticals Ltd. is a pharmaceutical company engaged in the research, development, production, and distribution of a diverse range of healthcare products.
Want to see everything about Senores Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Senores Pharmaceuticals do?
Senores Pharmaceuticals Ltd. is a pharmaceutical company engaged in the research, development, production, and distribution of a diverse range of healthcare products.
What is the chance SENORES.NSE goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, SENORES.NSE ends the month between ₹1,159 and ₹1,335.
How big is Senores Pharmaceuticals and what is its P/E ratio?
Senores Pharmaceuticals's market capitalization is ₹57.7B. Its price-to-earnings (P/E) ratio is 44.2: you pay ₹44.2 for each ₹1.00 of yearly earnings.
How volatile is SENORES.NSE?
ATLAS estimates annual volatility at 39%. In a typical month, half of the outcomes end between ₹1,159 and ₹1,335.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer